Home ivps4 2017-06-16T21:39:52+00:00

Investors Home

Achieve Life Sciences is a specialty pharmaceutical company committed to addressing the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.

Click here to access our latest corporate presentation.

Stock Info

Recent Press Releases

Recent News

Jul 22, 2021

Achieve Life Sciences Awarded Grant from the National Institutes of Health (NIH) for the Evaluation of Cytisinicline in Cessation of Nicotine E-cigarette Use

SEATTLE, Wash and VANCOUVER, British Columbia, July 22, 2021 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and...

Jun 29, 2021

Achieve Announces Completion of Target Enrollment of 750 Subjects in Phase 3 ORCA-2 Smoking Cessation Trial of Cytisinicline

ORCA-2 Designed to Assess the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing Compared to Placebo in Adult Smokers in the United States SEATTLE, Wash and VANCOUVER, British...

Jun 3, 2021

Achieve Announces Allowance of U.S. Patents for Dosing and Administration of Cytisinicline for the Treatment and Prevention of Addiction

SEATTLE, Wash and VANCOUVER, British Columbia, June 3, 2021 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and...